SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

TSP-101

ARGX·ARGENX SE
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
Unknown, at least 5-7+ years if successful. The drug is only in Phase 1 testing (safety/PK in healthy volunteers), with no Phase 2 or Phase 3 trials initiated yet.
Why 2/10
No hard dated binary catalyst (PDUFA, pivotal readout) is scheduled for TSP-101 in the next ~12 months. The drug is in early Phase 1 testing with no specific topline readout date announced. For argenx, TSP-101 is a very early-stage collaboration asset representing a negligible fraction of the company's value, argenx's ~$20B+ market cap is driven by its approved product Vyvgart.
Actionable Insight NEUTRAL

TSP-101 is a very early-stage (Phase 1) asset for argenx, representing a tiny fraction of the company's value. Argenx's near-term stock movement will be driven by its approved product Vyvgart and later-stage pipeline programs (ARGX-121, ARGX-124, ARGX-213), not TSP-101. Watch for Phase 1 safety/PK data readouts from Tensegrity Pharma, but these are unlikely to move ARGX shares materially.

Price Chart

Loading chart...

Executive Summary

TSP-101 (also known as ARGX-101) is a fully human monoclonal antibody targeting the Fn14/TWEAK receptor pathway, being developed by Tensegrity Pharma in collaboration with argenx SE (Nasdaq: ARGX). It is being investigated primarily for cancer cachexia (severe muscle wasting in cancer patients) and potentially for autoimmune diseases. The drug is in early Phase 1 clinical development, a first-in-human trial began dosing in Japan in December 2025. Argenx's involvement is through a research collaboration with an option to acquire Tensegrity Pharma. For argenx, a ~$20B+ market-cap biotech with an approved blockbuster (Vyvgart), TSP-101 is a very early-stage, low-concentration pipeline asset unlikely to drive near-term stock movement.

How It Works

TSP-101 is a monoclonal antibody (a type of lab-made immune protein) that blocks the Fn14 receptor, also known as TWEAK receptor. The TWEAK/Fn14 pathway is involved in inflammation and tissue wasting. By blocking this signal, TSP-101 aims to reduce the severe muscle wasting (cachexia) that affects many cancer patients, as well as potentially treat certain autoimmune diseases.

Trial Status

A first-in-human Phase 1 clinical trial (NCT04993768) was initiated in Japan. The first subject was dosed in December 2025. The study evaluates safety, tolerability, and pharmacokinetics of a single dose in healthy adult male volunteers. No efficacy data have been reported yet. Argenx's 2026 outlook lists TSP-101 as one of three new molecules expected to enter Phase 1 trials in 2026.

The Two-Sided Case

▲ Bull Case4
TSP-101 targets the Fn14/TWEAK pathway, a novel mechanism for cancer cachexia, a condition with high unmet medical need affecting a large population of cancer patients, with no approved targeted therapies.
Argenx's collaboration includes an option for future acquisition of Tensegrity Pharma, giving argenx a potential path to full ownership of the program if Phase 1 data are promising.
The drug has received support from AMED (Japan Agency for Medical Research and Development), providing non-dilutive funding and validation of the scientific approach.
Phase 1 dosing has already begun in Japan (first subject dosed December 2025), and argenx's 2026 outlook explicitly includes TSP-101 as one of three new molecules expected to enter Phase 1 in 2026.
▼ Bear Case4
TSP-101 is only in Phase 1 testing, the vast majority of Phase 1 assets fail before reaching the market, and cancer cachexia is a notoriously difficult indication with no FDA-approved targeted therapies.
Argenx's involvement is through a research collaboration with an option to acquire Tensegrity Pharma, not direct development, argenx can walk away without significant financial damage, but that also means limited upside for ARGX shareholders from this asset.
The drug was originally discontinued by Astellas Pharma for strategic reasons before Tensegrity Pharma revived it, prior abandonment raises questions about the underlying science.
For argenx, TSP-101 is a tiny, early-stage pipeline filler. The company's ~$20B+ market cap is overwhelmingly driven by its approved drug Vyvgart (efgartigimod). Even if TSP-101 succeeds, its contribution to argenx's valuation would be negligible for years.

Upcoming Catalysts

  • Phase 1 safety and pharmacokinetics data readout (no specific date announced)
  • Potential expansion of the collaboration or exercise of argenx's option to acquire Tensegrity Pharma (no timeline disclosed)
  • Initiation of Phase 1/2 trials in cancer cachexia patients (timeline TBD based on Phase 1 healthy volunteer results)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARGENX SE 6-K ARGX ·Originating report

Sources · 10

Hover a chip for the title
1 synapse.patsnap.com2 tensegritypharma.com3 gosset.ai4 argenx.com5 tensegritypharma.com6 reports.argenx.com7 adisinsight.springer.com8 tensegritypharma.com9 adisinsight.springer.com10 clinicaltrials.gov